These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 15161033

  • 1. Down-regulation of the human tumor antigen mucin by gemcitabine on the pancreatic cancer cell line capan-2.
    Dorn DC, Harnack U, Pecher G.
    Anticancer Res; 2004; 24(2B):821-5. PubMed ID: 15161033
    [Abstract] [Full Text] [Related]

  • 2. Mucin production determines sensitivity to bortezomib and gemcitabine in pancreatic cancer cells.
    Wissniowski TT, Meister S, Hahn EG, Kalden JR, Voll R, Ocker M.
    Int J Oncol; 2012 May; 40(5):1581-9. PubMed ID: 22266985
    [Abstract] [Full Text] [Related]

  • 3. Apicidin sensitizes pancreatic cancer cells to gemcitabine by epigenetically regulating MUC4 expression.
    Ansari D, Urey C, Hilmersson KS, Bauden MP, Ek F, Olsson R, Andersson R.
    Anticancer Res; 2014 Oct; 34(10):5269-76. PubMed ID: 25275019
    [Abstract] [Full Text] [Related]

  • 4. The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family.
    Skrypek N, Duchêne B, Hebbar M, Leteurtre E, van Seuningen I, Jonckheere N.
    Oncogene; 2013 Mar 28; 32(13):1714-23. PubMed ID: 22580602
    [Abstract] [Full Text] [Related]

  • 5. Calcitriol Reverses Induced Expression of Efflux Proteins and Potentiates Cytotoxic Activity of Gemcitabine in Capan-2 Pancreatic Cancer Cells.
    Gilzad-Kohan H, Sani S, Boroujerdi M.
    J Pharm Pharm Sci; 2017 Mar 28; 20(0):295-304. PubMed ID: 28885916
    [Abstract] [Full Text] [Related]

  • 6. Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines.
    Giovannetti E, Mey V, Danesi R, Mosca I, Del Tacca M.
    Clin Cancer Res; 2004 May 01; 10(9):2936-43. PubMed ID: 15131028
    [Abstract] [Full Text] [Related]

  • 7. Interdependence of gemcitabine treatment, transporter expression, and resistance in human pancreatic carcinoma cells.
    Hagmann W, Jesnowski R, Löhr JM.
    Neoplasia; 2010 Sep 01; 12(9):740-7. PubMed ID: 20824050
    [Abstract] [Full Text] [Related]

  • 8. Down-regulation of deoxycytidine kinase enhances acquired resistance to gemcitabine in pancreatic cancer.
    Ohhashi S, Ohuchida K, Mizumoto K, Fujita H, Egami T, Yu J, Toma H, Sadatomi S, Nagai E, Tanaka M.
    Anticancer Res; 2008 Sep 01; 28(4B):2205-12. PubMed ID: 18751396
    [Abstract] [Full Text] [Related]

  • 9. Pancreatic cancer cells surviving gemcitabine treatment express markers of stem cell differentiation and epithelial-mesenchymal transition.
    Quint K, Tonigold M, Di Fazio P, Montalbano R, Lingelbach S, Rückert F, Alinger B, Ocker M, Neureiter D.
    Int J Oncol; 2012 Dec 01; 41(6):2093-102. PubMed ID: 23026911
    [Abstract] [Full Text] [Related]

  • 10. Enhancement of the antiproliferative activity of gemcitabine by modulation of c-Met pathway in pancreatic cancer.
    Avan A, Quint K, Nicolini F, Funel N, Frampton AE, Maftouh M, Pelliccioni S, Schuurhuis GJ, Peters GJ, Giovannetti E.
    Curr Pharm Des; 2013 Dec 01; 19(5):940-50. PubMed ID: 22973962
    [Abstract] [Full Text] [Related]

  • 11. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
    McDonald PC, Chafe SC, Brown WS, Saberi S, Swayampakula M, Venkateswaran G, Nemirovsky O, Gillespie JA, Karasinska JM, Kalloger SE, Supuran CT, Schaeffer DF, Bashashati A, Shah SP, Topham JT, Yapp DT, Li J, Renouf DJ, Stanger BZ, Dedhar S.
    Gastroenterology; 2019 Sep 01; 157(3):823-837. PubMed ID: 31078621
    [Abstract] [Full Text] [Related]

  • 12. TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer.
    Tan Y, Li X, Tian Z, Chen S, Zou J, Lian G, Chen S, Huang K, Chen Y.
    Biochem Pharmacol; 2021 Jul 01; 189():114085. PubMed ID: 32522594
    [Abstract] [Full Text] [Related]

  • 13. Antiprotease strategy in pancreatic cancer treatment: emergence from a preclinical study.
    Brandi G, Tavolari S, Guarnieri T, Di Marco M, Paterini P, Macchini M, Di Girolamo S, Papi A, De Rosa F, Biasco G.
    Pancreas; 2014 Jan 01; 43(1):53-63. PubMed ID: 24201777
    [Abstract] [Full Text] [Related]

  • 14. Intrinsic chemoresistance to gemcitabine is associated with decreased expression of BNIP3 in pancreatic cancer.
    Akada M, Crnogorac-Jurcevic T, Lattimore S, Mahon P, Lopes R, Sunamura M, Matsuno S, Lemoine NR.
    Clin Cancer Res; 2005 Apr 15; 11(8):3094-101. PubMed ID: 15837765
    [Abstract] [Full Text] [Related]

  • 15. Synergy of gemcitabine and lidamycin associated with NF-kappaB downregulation in pancreatic carcinoma cells.
    Chen J, Wu SY, Ou-Yang ZG, Zhen YS.
    Acta Pharmacol Sin; 2008 May 15; 29(5):614-9. PubMed ID: 18430374
    [Abstract] [Full Text] [Related]

  • 16. TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3.
    Hesler RA, Huang JJ, Starr MD, Treboschi VM, Bernanke AG, Nixon AB, McCall SJ, White RR, Blobe GC.
    Carcinogenesis; 2016 Nov 01; 37(11):1041-1051. PubMed ID: 27604902
    [Abstract] [Full Text] [Related]

  • 17. Elucidation of the relationship of BNIP3 expression to gemcitabine chemosensitivity and prognosis.
    Ishida M, Sunamura M, Furukawa T, Akada M, Fujimura H, Shibuya E, Egawa S, Unno M, Horii A.
    World J Gastroenterol; 2007 Sep 14; 13(34):4593-7. PubMed ID: 17729412
    [Abstract] [Full Text] [Related]

  • 18. Rab14 overexpression regulates gemcitabine sensitivity through regulation of Bcl-2 and mitochondrial function in pancreatic cancer.
    Ge J, Ge C.
    Virchows Arch; 2019 Jan 14; 474(1):59-69. PubMed ID: 30267303
    [Abstract] [Full Text] [Related]

  • 19. Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer.
    Azorsa DO, Gonzales IM, Basu GD, Choudhary A, Arora S, Bisanz KM, Kiefer JA, Henderson MC, Trent JM, Von Hoff DD, Mousses S.
    J Transl Med; 2009 Jun 11; 7():43. PubMed ID: 19519883
    [Abstract] [Full Text] [Related]

  • 20. Effect of Gemcitabine based chemotherapy on the immunogenicity of pancreatic tumour cells and T-cells.
    Smith PL, Yogaratnam Y, Samad M, Kasow S, Dalgleish AG.
    Clin Transl Oncol; 2021 Jan 11; 23(1):110-121. PubMed ID: 32661823
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.